Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The CurePSP Genetics Program

NCT06647641 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT06647641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06647641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The CurePSP Genetics Program
Lead sponsor
Massachusetts General Hospital
Phase
Observational
Overall status
Recruiting
Start date
October 8, 2024
Completion date
December 31, 2030
Enrollment
1,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

corticobasal degeneration, corticobasal degeneration (cbd), corticobasal degeneration syndrome, corticobasal syndrome, corticobasal syndrome (cbs), corticobasal syndrome(cbs), msa, msa - multiple system atrophy, msa-c, multiple system atrophy, multiple system atrophy (msa) with orthostatic hypotension, multiple system atrophy - cerebellar subtype (msa-c), multiple system atrophy - parkinsonian subtype (msa-p), multiple system atrophy, cerebellar type, multiple system atrophy, parkinsonian type, progressive supranuclear palsy, progressive supranuclear palsy (psp), progressive supranuclear palsy(psp), psp, psp - progressive supranuclear palsy